Yu-Na Chae

Title: Innovations of Yu-Na Chae in Metabolic Disease Treatment

Introduction

Yu-Na Chae is a prominent inventor based in Yongin-si, South Korea. She has made significant contributions to the field of metabolic disease treatment, particularly through her innovative peptide analogs. With a total of two patents to her name, her work focuses on addressing obesity and diabetes.

Latest Patents

Yu-Na Chae's latest patents include a novel peptide analog of acylated oxyntomodulin. This innovative peptide analog and its pharmaceutical composition are designed to prevent and treat obesity or overweightness, as well as diabetes associated with these conditions. The peptide analog demonstrates superior dual agonism on GLP-1 and glucagon receptors compared to wild-type oxyntomodulin, along with a longer in vivo half-life. This advancement is crucial for developing effective treatments for metabolic diseases such as obesity and diabetes mellitus.

Career Highlights

Yu-Na Chae is currently associated with Dong-a St Co., Ltd., where she continues to advance her research and development efforts. Her work has garnered attention for its potential impact on public health, particularly in combating the obesity epidemic and related metabolic disorders.

Collaborations

Yu-Na collaborates with notable colleagues, including Jae-Sung Yang and Kyung-Seok Lee. Their combined expertise enhances the research and development process, leading to innovative solutions in the field of metabolic disease treatment.

Conclusion

Yu-Na Chae's contributions to the development of peptide analogs for treating obesity and diabetes highlight her role as a leading inventor in the field. Her innovative work promises to make a significant impact on the management of metabolic diseases.